Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 455.6%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 261,700 shares, a growth of 455.6% from the July 15th total of 47,100 shares. Based on an average daily volume of 897,900 shares, the short-interest ratio is currently 0.3 days. Currently, 59.3% of the shares of the company are short sold.

Windtree Therapeutics Trading Down 4.5 %

Shares of NASDAQ WINT traded down $0.56 during trading hours on Monday, reaching $11.80. The stock had a trading volume of 35,991 shares, compared to its average volume of 392,790. The firm has a 50-day moving average of $4.72 and a 200-day moving average of $5.55. The firm has a market cap of $6.99 million, a price-to-earnings ratio of -0.33 and a beta of 0.55. Windtree Therapeutics has a fifty-two week low of $2.81 and a fifty-two week high of $30.06.

Windtree Therapeutics (NASDAQ:WINT) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($9.25) earnings per share for the quarter. On average, equities analysts predict that Windtree Therapeutics will post -2.38 EPS for the current year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.